This suggests that the pro-tumoral functions of CD163+ TAMs in HER2+ breast cancer are not obstructed by trastuzumab or that CD163+ TAMs might even suppress its actions, even though patients with a high CD163+ TAM count also benefitted from the adjuvant trastuzumab therapy. This evidence concerns the gene ERBB2 and breast carcinoma.